Risk of HCC: Genetic heterogeneity and complex genetics

Journal of Hepatology

Volumn 52, Issue 2, 2010, Pages 252-257

  Dragani, Tommaso A ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cirrhosis; Glycogen storage disease; Hemochromatosis; Hepatitis; Non alcoholic steatohepatitis; Porphyrias; Tyrosinemia type I

Indexed keywords

AFLATOXIN;

ALPHA 1 ANTITRYPSIN DEFICIENCY; AUTOIMMUNE HEPATITIS; ENVIRONMENTAL FACTOR; EPIDEMIOLOGICAL DATA; FAMILY HISTORY; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GLYCOGEN STORAGE DISEASE TYPE 1; HEMOCHROMATOSIS; HIGH RISK POPULATION; HUMAN; HYPOTHYROIDISM; INCIDENCE; LIVER CELL CARCINOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PORPHYRIA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TYROSINEMIA;

ALPHA 1-ANTITRYPSIN DEFICIENCY; CARCINOMA, HEPATOCELLULAR; DIABETES COMPLICATIONS; FATTY LIVER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLYCOGEN STORAGE DISEASE TYPE I; HEMOCHROMATOSIS; HEPATITIS, AUTOIMMUNE; HUMANS; HYPOTHYROIDISM; LIVER NEOPLASMS; MALE; MODELS, GENETIC; PORPHYRIAS, HEPATIC; RISK FACTORS; TYROSINEMIAS;

EID: 75349084543     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.11.015     Document Type: Review

References (74)

1. Bosch F.X., Ribes J., Diaz M., and Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127 (2004) S5-S16
2. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 (2003) 1907-1917
3. Evans A.A., Chen G., Ross E.A., Shen F.M., Lin W.Y., and London W.T. Eight-year follow-up of the 90,000-person Haimen City cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomarkers Prev 11 (2002) 369-376
4. Franceschi S., Montella M., Polesel J., La Vecchia C., Crispo A., Dal Maso L., et al. Hepatitis viruses, alcohol, and tobacco in the etiology of hepatocellular carcinoma in Italy. Cancer Epidemiol Biomarkers Prev 15 (2006) 683-689
5. IARC. Hepatitis viruses. IARC Monogr Eval Carcinog Risks Hum 59 (1994) 1-255
6. El Serag H.B., and Mason A.C. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 160 (2000) 3227-3230
7. Ogimoto I., Shibata A., Kurozawa Y., Nose T., Yoshimura T., Suzuki H., et al. Risk of death due to hepatocellular carcinoma among drinkers and ex-drinkers. Univariate analysis of JACC study data. Kurume Med J 51 (2004) 59-70
8. Kuper H., Tzonou A., Kaklamani E., Hsieh C.C., Lagiou P., Adami H.O., et al. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 85 (2000) 498-502
9. Baan R., Straif K., Grosse Y., Secretan B., el Ghissassi F., Bouvard V., et al. Carcinogenicity of alcoholic beverages. Lancet Oncol 8 (2007) 292-293
10. IARC. Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. IARC Monogr Eval Carcinog Risks Hum 82 (2002) 171-300
11. IARC. Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum 83 (2004) 1-1438
12. Dragani T.A., Canzian F., Manenti G., and Pierotti M.A. Hepatocarcinogenesis: a polygenic model of inherited predisposition to cancer. Tumori 82 (1996) 1-5
13. Feo F., De Miglio M.R., Simile M.M., Muroni M.R., Calvisi D.F., Frau M., et al. Hepatocellular carcinoma as a complex polygenic disease. Interpretive analysis of recent developments on genetic predisposition. Biochim Biophys Acta 1765 (2006) 126-147
14. Fairbanks K.D., and Tavill A.S. Liver disease in alpha 1-antitrypsin deficiency: a review. Am J Gastroenterol 103 (2008) 2136-2141
15. Elzouki A.N., and Eriksson S. Risk of hepatobiliary disease in adults with severe alpha 1-antitrypsin deficiency (PiZZ): is chronic viral hepatitis B or C an additional risk factor for cirrhosis and hepatocellular carcinoma?. Eur J Gastroenterol Hepatol 8 (1996) 989-994
16. Janecke A.R., Mayatepek E., and Utermann G. Molecular genetics of type 1 glycogen storage disease. Mol Genet Metab 73 (2001) 117-125
17. Lee P.J. Glycogen storage disease type I: pathophysiology of liver adenomas. Eur J Pediatr 161 Suppl. 1 (2002) S46-S49
18. Rake J.P., Visser G., Labrune P., Leonard J.V., Ullrich K., and Smit G.P. Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 161 Suppl. 1 (2002) S20-S34
19. Franco L.M., Krishnamurthy V., Bali D., Weinstein D.A., Arn P., Clary B., et al. Hepatocellular carcinoma in glycogen storage disease type Ia: a case series. J Inherit Metab Dis 28 (2005) 153-162
20. Bianchi L. Glycogen storage disease I and hepatocellular tumours. Eur J Pediatr 152 Suppl. 1 (1993) S63-S70
21. Alexander J., and Kowdley K.V. HFE-associated hereditary hemochromatosis. Genet Med 11 (2009) 307-313
22. Pietrangelo A. Hereditary hemochromatosis-a new look at an old disease. N Engl J Med 350 (2004) 2383-2397
23. Olynyk J.K., Trinder D., Ramm G.A., Britton R.S., and Bacon B.R. Hereditary hemochromatosis in the post-HFE era. Hepatology 48 (2008) 991-1001
24. Elmberg M., Hultcrantz R., Ekbom A., Brandt L., Olsson S., Olsson R., et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 125 (2003) 1733-1741
25. Haddow J.E., Palomaki G.E., McClain M., and Craig W. Hereditary haemochromatosis and hepatocellular carcinoma in males: a strategy for estimating the potential for primary prevention. J Med Screen 10 (2003) 11-13
26. Seth A.K., Badminton M.N., Mirza D., Russell S., and Elias E. Liver transplantation for porphyria: who, when, and how?. Liver Transpl 13 (2007) 1219-1227
27. Ulbrichova D., Hrdinka M., Saudek V., and Martasek P. Acute intermittent porphyria - impact of mutations found in the hydroxymethylbilane synthase gene on biochemical and enzymatic protein properties. FEBS J 276 (2009) 2106-2115
28. Ostrowski J., Kostrzewska E., Michalak T., Zawirska B., Medrzejewski W., and Gregor A. Abnormalities in liver function and morphology and impaired aminopyrine metabolism in hereditary hepatic porphyrias. Gastroenterology 85 (1983) 1131-1137
29. Andant C., Puy H., Bogard C., Faivre J., Soule J.C., Nordmann Y., et al. Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. J Hepatol 32 (2000) 933-939
30. Badenas C., To-Figueras J., Phillips J.D., Warby C.A., Munoz C., and Herrero C. Identification and characterization of novel uroporphyrinogen decarboxylase gene mutations in a large series of porphyria cutanea tarda patients and relatives. Clin Genet 75 (2009) 346-353
31. Aarsand A.K., Boman H., and Sandberg S. Familial and sporadic porphyria cutanea tarda: characterization and diagnostic strategies. Clin Chem 55 (2009) 795-803
32. Fracanzani A.L., Taioli E., Sampietro M., Fatta E., Bertelli C., Fiorelli G., et al. Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease. J Hepatol 35 (2001) 498-503
33. Solis J.A., Betancor P., Campos R., Enriquez de Salamanca R.E., Rojo P., Marin I., et al. Association of porphyria cutanea tarda and primary liver cancer: report of ten cases. J Dermatol 9 (1982) 131-137
34. Salata H., Cortes J.M., Enriquez D.S., Oliva H., Castro A., Kusak E., et al. Porphyria cutanea tarda and hepatocellular carcinoma. Frequency of occurrence and related factors. J Hepatol 1 (1985) 477-487
35. Gisbert J.P., Garcia-Buey L., Pajares J.M., and Moreno-Otero R. Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol 39 (2003) 620-627
36. Scott C.R. The genetic tyrosinemias. Am J Med Genet C Semin Med Genet 142C (2006) 121-126
37. Weinberg A.G., Mize C.E., and Worthen H.G. The occurrence of hepatoma in the chronic form of hereditary tyrosinemia. J Pediatr 88 (1976) 434-438
38. Beland K., Lapierre P., and Alvarez F. Influence of genes, sex, age and environment on the onset of autoimmune hepatitis. World J Gastroenterol 15 (2009) 1025-1034
39. Werner M., Almer S., Prytz H., Lindgren S., Wallerstedt S., Bjornsson E., et al. Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients. J Hepatol 50 (2009) 388-393
40. Nussbaum T., Samarin J., Ehemann V., Bissinger M., Ryschich E., Khamidjanov A., et al. Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis. Hepatology 48 (2008) 146-156
41. El Serag H.B., Hampel H., and Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 4 (2006) 369-380
42. Florez J.C. Clinical review: the genetics of type 2 diabetes: a realistic appraisal in 2008. J Clin Endocrinol Metab 93 (2008) 4633-4642
43. Salanti G., Southam L., Altshuler D., Ardlie K., Barroso I., Boehnke M., et al. Underlying genetic models of inheritance in established type 2 diabetes associations. Am J Epidemiol 170 (2009) 537-545
44. Adami H.O., Chow W.H., Nyren O., Berne C., Linet M.S., Ekbom A., et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 88 (1996) 1472-1477
45. Hassan M.M., Hwang L.Y., Hatten C.J., Swaim M., Li D., Abbruzzese J.L., et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 36 (2002) 1206-1213
46. Hjalgrim H., Frisch M., Ekbom A., Kyvik K.O., Melbye M., and Green A. Cancer and diabetes - a follow-up study of two population-based cohorts of diabetic patients. J Intern Med 241 (1997) 471-475
47. Hemminki K., and Li X. Familial liver and gall bladder cancer: a nationwide epidemiological study from Sweden. Gut 52 (2003) 592-596
48. Shen F.M., Lee M.K., Gong H.M., Cai X.Q., and King M.C. Complex segregation analysis of primary hepatocellular carcinoma in Chinese families: interaction of inherited susceptibility and hepatitis B viral infection. Am J Hum Genet 49 (1991) 88-93
49. Shih W.L., Yu M.W., Chen P.J., Yeh S.H., Lo M.T., Chang H.C., et al. Localization of a susceptibility locus for hepatocellular carcinoma to chromosome 4q in a hepatitis B hyperendemic area. Oncogene 25 (2006) 3219-3224
50. Shih W.L., Yu M.W., Chen P.J., Wu T.W., Lin C.L., Liu C.J., et al. Evidence for association with hepatocellular carcinoma at the PAPSS1 locus on chromosome 4q25 in a family-based study. Eur J Hum Genet 17 (2009) 1250-1259
51. Aoki Y., Belin R.M., Clickner R., Jeffries R., Phillips L., and Mahaffey K.R. Serum TSH and total T4 in the United States population and their association with participant characteristics: National Health and Nutrition Examination Survey (NHANES 1999-2002). Thyroid 17 (2007) 1211-1223
52. Hassan M.M., Kaseb A., Li D., Patt Y.Z., Vauthey J.N., Thomas M.B., et al. Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology 49 (2009) 1563-1570
53. Liangpunsakul S., and Chalasani N. Is hypothyroidism a risk factor for non-alcoholic steatohepatitis?. J Clin Gastroenterol 37 (2003) 340-343
54. Hashimoto E., Yatsuji S., Tobari M., Taniai M., Torii N., Tokushige K., et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol 44 Suppl. 19 (2009) 89-95
55. Yatsuji S., Hashimoto E., Tobari M., Taniai M., Tokushige K., and Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 24 (2009) 248-254
56. Luedde T., Beraza N., Kotsikoris V., van Loo G., Nenci A., De Vos R., et al. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 11 (2007) 119-132
57. Hill-Baskin A.E., Markiewski M.M., Buchner D.A., Shao H., Desantis D., Hsiao G., et al. Diet-induced hepatocellular carcinoma in genetically-predisposed mice. Hum Mol Genet 18 (2009) 2975-2988
58. Wild C.P., and Turner P.C. The toxicology of aflatoxins as a basis for public health decisions. Mutagenesis 17 (2002) 471-481
59. Wojnowski L., Turner P.C., Pedersen B., Hustert E., Brockmoller J., Mendy M., et al. Increased levels of aflatoxin-albumin adducts are associated with CYP3A5 polymorphisms in The Gambia, West Africa. Pharmacogenetics 14 (2004) 691-700
60. Chen X., Wang H., Xie W., Liang R., Wei Z., Zhi L., et al. Association of CYP1A2 genetic polymorphisms with hepatocellular carcinoma susceptibility: a case-control study in a high-risk region of China. Pharmacogenet Genomics 16 (2006) 219-227
61. White D.L., Li D., Nurgalieva Z., and El Serag H.B. Genetic variants of glutathione S-transferase as possible risk factors for hepatocellular carcinoma: a HuGE systematic review and meta-analysis. Am J Epidemiol 167 (2008) 377-389
62. Wong N.A., Rae F., Simpson K.J., Murray G.D., and Harrison D.J. Genetic polymorphisms of cytochrome p4502E1 and susceptibility to alcoholic liver disease and hepatocellular carcinoma in a white population: a study and literature review, including meta-analysis. Mol Pathol 53 (2000) 88-93
63. Ding J., Li S., Wu J., Gao C., Zhou J., Cao H., et al. Alcohol dehydrogenase-2 and aldehyde dehydrogenase-2 genotypes, alcohol drinking and the risk of primary hepatocellular carcinoma in a Chinese population. Asian Pac J Cancer Prev 9 (2008) 31-35
64. Homann N., Stickel F., Konig I.R., Jacobs A., Junghanns K., Benesova M., et al. Alcohol dehydrogenase 1C*1 allele is a genetic marker for alcohol-associated cancer in heavy drinkers. Int J Cancer 118 (2006) 1998-2002
65. Nahon P., Sutton A., Rufat P., Ziol M., Akouche H., Laguillier C., et al. Myeloperoxidase and SOD2 polymorphisms comodulate the risk of hepatocellular carcinoma and death in alcoholic cirrhosis. Hepatology 50 (2009) 1484-1493
66. El Serag H.B., and Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132 (2007) 2557-2576
67. La Vecchia C., Negri E., Cavalieri d.L., and Franceschi S. Liver cirrhosis and the risk of primary liver cancer. Eur J Cancer Prev 7 (1998) 315-320
68. Garcia-Compean D., Jaquez-Quintana J.O., Gonzalez-Gonzalez J.A., and Maldonado-Garza H. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol 15 (2009) 280-288
69. Dragani T.A., Manenti G., and Della Porta G. Enhancing effects of carbon tetrachloride in mouse hepatocarcinogenesis. Cancer Lett 31 (1986) 171-179
70. Gariboldi M., Manenti G., Canzian F., Falvella F.S., Pierotti M.A., Della Porta G., et al. Chromosome mapping of murine susceptibility loci to liver carcinogenesis. Cancer Res 53 (1993) 209-211
71. Manenti G., Binelli G., Gariboldi M., Canzian F., De Gregorio L., Falvella F.S., et al. Multiple loci affect genetic predisposition to hepatocarcinogenesis in mice. Genomics 23 (1994) 118-124
72. Manenti G., Galvan A., Falvella F.S., Pascale R.M., Spada E., Milani S., et al. Genetic control of resistance to hepatocarcinogenesis by the mouse Hpcr3 locus. Hepatology 48 (2008) 617-623
73. De Miglio M.R., Canzian F., Pascale R.M., Simile M.M., Muroni M.R., Calvisi D., et al. Identification of genetic loci controlling hepatocarcinogenesis on rat chromosomes 7 and 10. Cancer Res 59 (1999) 4651-4657
74. De Miglio M.R., Pascale R.M., Simile M.M., Muroni M.R., Virdis P., Kwong K.M., et al. Polygenic control of hepatocarcinogenesis in Copenhagen x F344 rats. Int J Cancer 111 (2004) 9-16